Annual Report

Overview

The report presents the Group's 2018 performance across pharmaceutical R&D, commercialization and ESG. It reports consolidated revenue of RMB 740,422,000 and describes continued development of four R&D platforms. The ESG section covers the Group's 1 January to 31 December 2018 operations and states that the Board takes full responsibility for ESG strategy and reporting.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2018
Period: 1 January 2018 – 31 December 2018
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services